GlaxoSmithKline (GSK) has shortlisted a group of private equity funds and strategic bidders for the sale of its non-core over-the-counter products. The bidders include private equity funds Bain Capital, Blackstone and German pharmaceutical group Boehringer Ingelheim.
The sale will fetch the U.K. pharmaceutical company an estimated £1.5 billion. Other interested firms include Thomas H. Lee Partners, Bayer Group and Brussels-listed pharmaceutical company Omega Pharma. Final-round bids are likely to be tendered at the end of September or early October. The process is being managed by Goldman Sachs.
Click here for the story from Financial Times.
Click here for additional coverage from Reuters.